首页> 外文期刊>Arquivos Brasileiros de Oftalmologia >Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization
【24h】

Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization

机译:结膜下和局部抗VEGF治疗(贝伐单抗)对实验性角膜新生血管作用的比较

获取原文
获取外文期刊封面目录资料

摘要

Purpose: To compare the effects of bevacizumab applied either subconjunctivally or topically, in a rat model of corneal neovascularization induced by alkali burn. Methods: The right corneas of 24 Wistar-Albino rats were cauterized with silver nitrate sticks. The rats were divided randomly and equally into three groups: no treatment control (n=8), subconjunctival bevacizumab treatment (n=8), and topical bevacizumab treatment (n=8). Immediately following cauterization, the subconjunctival group was treated with a 0.05 ml (1.25 mg) bevacizumab subconjunctival injection. The topical group was treated with 10 mg/ml bevacizumab twice daily, and the control group received subconjunctival saline injections twice daily. The burn stimulus and neovascularization scores were evaluated using a technique previously described by Mahoney and Waterbury. Digital photographs were obtained before the eyes were enucleated and corneal sections were then analyzed by histopathology. Results: The mean burn stimulus score was 1.86 ± 0.6 and there was no statistical difference between the groups (p=0.730). The mean neovascularization scores in the subconjunctival and topical bevacizumab groups were statistically lower than the control group (p0.05). The mean percentage area of corneal neovascularization was 82.5 ± 22.1 in the control group, 42.7 ± 15.0 in the subconjunctival group, and 55.8 ± 18.2 in the topical group. The differences between the control and treatment groups were statistically significant (p0.05). Histopathology showed that the treatment groups presented less neovascularization, inflammation, and fibroblast activity than the control group (p0.05). Conclusions: This study demonstrates that both subconjunctival and topical administrations of bevacizumab inhibit corneal neovascularization and decrease inflammation and fibroblast activity in a rat model of corneal neovascularization induced by alkali burn.
机译:目的:为了比较贝伐单抗在结膜烧伤或碱​​烧伤大鼠角膜新生血管模型中结膜下或局部使用的效果。方法:用硝酸银棒烧灼24只Wistar-Albino大鼠的右角膜。将大鼠随机分为三组:无治疗对照组(n = 8),结膜下贝伐单抗治疗(n = 8)和局部贝伐单抗治疗(n = 8)。烧灼后,立即用0.05 ml(1.25 mg)贝伐单抗结膜下注射治疗结膜下组。局部组每天两次用10 mg / ml贝伐单抗治疗,对照组每天两次结膜下注射盐水。使用先前由Mahoney和Waterbury描述的技术评估烧伤刺激和新血管形成分数。在摘除眼球之前先获得数码照片,然后通过组织病理学分析角膜切片。结果:平均烧伤刺激评分为1.86±0.6,两组之间无统计学差异(p = 0.730)。结膜下和局部贝伐单抗组的平均新血管形成评分在统计学上低于对照组(p <0.05)。对照组角膜新生血管的平均面积百分比为82.5±22.1,结膜下组为42.7±15.0,局部组为55.8±18.2。对照组和治疗组之间的差异具有统计学意义(p <0.05)。组织病理学显示,治疗组的新生血管形成,炎症和成纤维细胞活性均低于对照组(p <0.05)。结论:这项研究表明,贝伐单抗的结膜下和局部给药均可抑制碱烧伤诱发的角膜新生血管模型的角膜新生血管形成,并降低炎症和成纤维细胞活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号